多西紫杉醇联合顺铂二线化疗对进展期晚期胃癌患者临床疗效研究

目的：观察多西紫杉醇联合顺铂二线化疗治疗晚期胃癌一线药物化疗后病情进展患者的疗效及安全性。方法将80例晚期胃癌一线奥沙利铂联合氟尿嘧啶类药物化疗后病情进展患者纳入研究，其中单药组32例：给予多西紫杉醇75～100 mg／m2治疗，21 d 为1个周期；联合组48例：给予多西紫杉醇60～75 mg／m2 d1，顺铂针25 mg／m2 d1～3，21 d 为1个周期。结果80例均可评价客观疗效及不良反应，单药组和联合组的有效率（RR）分别为12．5％和33．3％，疾病控制率（DCR）分别为43．8％和75．0％，联合组较单药组的 RR 及 DCR 均明显提高（P ＜0．05）。单药组的无疾病进展时间（PFS）为3．1月，联合组的 PFS 为3．9月，联合组较单药组有延长，但差异无统计学意义（P ＞0．05）。最常见的不良反应为血液学毒性、恶心呕吐和脱发，差异均无统计学意义（P ＞0．05）。结论晚期胃癌一线化疗进展患者采用多西紫杉醇联合顺铂方案有效率及疾病控制率较高，不良反应可耐受，仍需进一步研究。

Clinical observation of docetaxel combined with cisplatin as second-line chemotherapy in the treatment of advanced gastric carcinoma

ObjectiveTo observe the efficacy and safety of docetaxel and cisplatin as second-line chemotherapy af-ter failure of first-line oxaliplatin combined with fluorouracil chemotherapy for advanced gastric cancer,to investi-gate the eligible second-line chemotherapy.Methods Eighty patients of advanced gastric cancer after first-line oxali-platin and fluorouracil chemotherapy were selected in the study progress.Subgroup were single drug group (32 pa-tients)was used docetaxel 75~100 mg/ m2,d1,every twenty-one days was a cycle,and combined group (48 pa-tients)was used docetaxel 60~75mg/m2 ,d1,cisplatin 25mg/m2,day 1~3,every twenty-one days was a cycle. Results Eighty patients were evaluated efficacy and adverse event.The RR rates of the single drug group and com-bined group were 12.5% and,33.3% respectively.The DCR rates of the single drug group and combined group was 43.8% and 75.0%.There were statistical significantly differences between the RR and DCR with the combined group of the single drug group (P <0.05).The PFS of the single drug group was 3.1 months.The PFS of the combined group was 3.9 months.The combined group was longer than the single drug group,but there were no statistical significantly differences (P >0.05).The most common adverse effects were hematological toxicity,nau-sea and vomiting,and alopecia,and There were no statistical significantly differences (P >0.05).Conclusion Do-cetaxel combined with cisplatin for the failure of first-line chemotherapy for advanced gastric cancer gets a certain objective response rate and clinical benefit rate,adverse reactions can be tolerated,but still need further study.